{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:44:23Z","timestamp":1770270263574,"version":"3.49.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,6,23]],"date-time":"2018-06-23T00:00:00Z","timestamp":1529712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s11102-018-0898-y","type":"journal-article","created":{"date-parts":[[2018,6,23]],"date-time":"2018-06-23T04:19:51Z","timestamp":1529727591000},"page":"454-462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study"],"prefix":"10.1007","volume":"21","author":[{"given":"Winnie","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roula Shraiky","family":"Zahr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley","family":"McCartney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin S.","family":"Cetas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aclan","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-6289","authenticated-orcid":false,"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,23]]},"reference":[{"issue":"12","key":"898_CR1","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1210\/jc.2006-1668","volume":"91","author":"AF Daly","year":"2006","unstructured":"Daly AF et al (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91(12):4769\u20134775","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"898_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/cncr.20412","volume":"101","author":"S Ezzat","year":"2004","unstructured":"Ezzat S et al (2004) The prevalence of pituitary adenomas: a systematic review. Cancer 101(3):613\u2013619","journal-title":"Cancer"},{"issue":"3","key":"898_CR3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3171\/2014.5.JNS131819","volume":"121","author":"H Gittleman","year":"2014","unstructured":"Gittleman H et al (2014) Descriptive epidemiology of pituitary tumors in the United States, 2004\u20132009. J Neurosurg 121(3):527\u2013535","journal-title":"J Neurosurg"},{"issue":"1","key":"898_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11102-010-0253-4","volume":"14","author":"BD McDowell","year":"2011","unstructured":"McDowell BD et al (2011) Demographic differences in incidence for pituitary adenoma. Pituitary 14(1):23\u201330","journal-title":"Pituitary"},{"issue":"5","key":"898_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/er.2005-9998","volume":"27","author":"MP Gillam","year":"2006","unstructured":"Gillam MP et al (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485\u2013534","journal-title":"Endocr Rev"},{"issue":"4","key":"898_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11102-012-0454-0","volume":"16","author":"M Gruppetta","year":"2013","unstructured":"Gruppetta M, Mercieca C, Vassallo J (2013) Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 16(4):545\u2013553","journal-title":"Pituitary"},{"issue":"1","key":"898_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11102-005-5079-0","volume":"8","author":"A Ciccarelli","year":"2005","unstructured":"Ciccarelli A, Daly AF, Beckers A (2005) The epidemiology of prolactinomas. Pituitary 8(1):3\u20136","journal-title":"Pituitary"},{"issue":"8","key":"898_CR8","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jocn.2008.11.001","volume":"16","author":"CG Patil","year":"2009","unstructured":"Patil CG et al (2009) Non-surgical management of hormone-secreting pituitary tumors. J Clin Neurosci 16(8):985\u2013993","journal-title":"J Clin Neurosci"},{"issue":"3","key":"898_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","volume":"72","author":"A Fernandez","year":"2010","unstructured":"Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72(3):377\u2013382","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"898_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/eje.0.1480325","volume":"148","author":"A Colao","year":"2003","unstructured":"Colao A et al (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148(3):325\u2013331","journal-title":"Eur J Endocrinol"},{"issue":"13","key":"898_CR11","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1056\/NEJMcp0912025","volume":"362","author":"A Klibanski","year":"2010","unstructured":"Klibanski A (2010) Clinical practice. Prolactinomas. N Engl J Med 362(13):1219\u20131226","journal-title":"N Engl J Med"},{"issue":"7","key":"898_CR12","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00701-005-0498-2","volume":"147","author":"E Delgrange","year":"2005","unstructured":"Delgrange E et al (2005) Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochir (Wien) 147(7):751\u2013757; discussion 757\u20138","journal-title":"Acta Neurochir (Wien)"},{"issue":"2","key":"898_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 96(2):273\u2013288","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"898_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","volume":"65","author":"FF Casanueva","year":"2006","unstructured":"Casanueva FF et al (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65(2):265\u2013273","journal-title":"Clin Endocrinol (Oxf)"},{"key":"898_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-018-0888-0","author":"A Nakhleh","year":"2018","unstructured":"Nakhleh A et al (2018) Management of cystic prolactinomas: a review. Pituitary. \n                    https:\/\/doi.org\/10.1007\/s11102-018-0888-0","journal-title":"Pituitary"},{"issue":"5","key":"898_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00234-002-0774-2","volume":"44","author":"H Nishioka","year":"2002","unstructured":"Nishioka H et al (2002) Gender-related differences in prolactin secretion in pituitary prolactinomas. Neuroradiology 44(5):407\u2013410","journal-title":"Neuroradiology"},{"issue":"2","key":"898_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s12020-016-1225-x","volume":"56","author":"I Shimon","year":"2017","unstructured":"Shimon I (2017) Giant prolactinomas: multi-modal approach to achieve tumor control. Endocrine 56(2):227\u2013228","journal-title":"Endocrine"},{"issue":"4","key":"898_CR18","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00401-017-1769-8","volume":"134","author":"MBS Lopes","year":"2017","unstructured":"Lopes MBS (2017) The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 134(4):521\u2013535","journal-title":"Acta Neuropathol"},{"issue":"1","key":"898_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11102-017-0844-4","volume":"21","author":"F Langlois","year":"2018","unstructured":"Langlois F et al (2018) Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review. Pituitary 21(1):32\u201340","journal-title":"Pituitary"},{"issue":"2","key":"898_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11102-018-0864-8","volume":"21","author":"A Ben-Shlomo","year":"2018","unstructured":"Ben-Shlomo A, Cooper O (2018) Silent corticotroph adenomas. Pituitary 21(2):183\u2013193","journal-title":"Pituitary"},{"issue":"3","key":"898_CR21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11060-013-1270-8","volume":"117","author":"ME Molitch","year":"2014","unstructured":"Molitch ME (2014) Management of medically refractory prolactinoma. J Neurooncol 117(3):421\u2013428","journal-title":"J Neurooncol"},{"issue":"11","key":"898_CR22","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1210\/jc.2016-2118","volume":"101","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M et al (2016) Hormonal replacement in hypopituitarism in adults: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101(11):3888\u20133921","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"898_CR23","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12020-014-0259-1","volume":"47","author":"I Shimon","year":"2014","unstructured":"Shimon I et al (2014) Women with prolactinomas presented at the postmenopausal period. Endocrine 47(3):889\u2013894","journal-title":"Endocrine"},{"issue":"6","key":"898_CR24","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/BF03349742","volume":"18","author":"M Berezin","year":"1995","unstructured":"Berezin M, Shimon I, Hadani M (1995) Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma). J Endocrinol Invest 18(6):436\u2013441","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"898_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2265.2012.04351.x","volume":"77","author":"P Iglesias","year":"2012","unstructured":"Iglesias P et al (2012) Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome. Clin Endocrinol (Oxf) 77(2):281\u2013287","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"898_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1530\/EJE-06-0646","volume":"156","author":"I Shimon","year":"2007","unstructured":"Shimon I, Benbassat C, Hadani M (2007) Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 156(2):225\u2013231","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"898_CR27","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3171\/2010.11.JNS101369","volume":"114","author":"MC Oh","year":"2011","unstructured":"Oh MC, Aghi MK (2011) Dopamine agonist-resistant prolactinomas. J Neurosurg 114(5):1369\u20131379","journal-title":"J Neurosurg"},{"issue":"12","key":"898_CR28","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1210\/jc.2007-2758","volume":"93","author":"M Ono","year":"2008","unstructured":"Ono M et al (2008) Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 93(12):4721\u20134727","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"898_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ejim.2008.11.012","volume":"20","author":"M Kars","year":"2009","unstructured":"Kars M et al (2009) Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. Eur J Intern Med 20(4):387\u2013393","journal-title":"Eur J Intern Med"},{"issue":"4","key":"898_CR30","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11102-016-0723-4","volume":"19","author":"I Shimon","year":"2016","unstructured":"Shimon I et al (2016) Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas. Pituitary 19(4):429\u2013436","journal-title":"Pituitary"},{"issue":"10","key":"898_CR31","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/ncpendmet0290","volume":"2","author":"A Olafsdottir","year":"2006","unstructured":"Olafsdottir A, Schlechte J (2006) Management of resistant prolactinomas. Nat Clin Pract Endocrinol Metab 2(10):552\u2013561","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"7","key":"898_CR32","first-page":"2102","volume":"82","author":"E Delgrange","year":"1997","unstructured":"Delgrange E et al (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82(7):2102\u20132107","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"898_CR33","first-page":"3053","volume":"85","author":"JJ Pinzone","year":"2000","unstructured":"Pinzone JJ et al (2000) Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 85(9):3053\u20133057","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"898_CR34","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1210\/jc.2009-0177","volume":"94","author":"M Kars","year":"2009","unstructured":"Kars M et al (2009) Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab 94(8):2729\u20132734","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"898_CR35","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1210\/er.2015-1042","volume":"36","author":"C Briet","year":"2015","unstructured":"Briet C et al (2015) Pituitary apoplexy. Endocr Rev 36(6):622\u2013645","journal-title":"Endocr Rev"},{"issue":"6","key":"898_CR36","first-page":"841","volume":"28","author":"M Vaneckova","year":"2007","unstructured":"Vaneckova M et al (2007) Macroprolactinomas: retrospective follow up study in the MR imaging and correlation with clinical symptomatology. Neuro Endocrinol Lett 28(6):841\u2013845","journal-title":"Neuro Endocrinol Lett"},{"key":"898_CR37","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1476-4598-6-4","volume":"6","author":"C Cristina","year":"2007","unstructured":"Cristina C et al (2007) PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes. Mol Cancer 6:4","journal-title":"Mol Cancer"},{"issue":"6","key":"898_CR38","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1530\/EJE-14-0990","volume":"172","author":"E Delgrange","year":"2015","unstructured":"Delgrange E et al (2015) Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. Eur J Endocrinol 172(6):791\u2013801","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"898_CR39","first-page":"174","volume":"35","author":"H Lv","year":"2012","unstructured":"Lv H et al (2012) Expression of estrogen receptor alpha and growth factors in human prolactinoma and its correlation with clinical features and gender. J Endocrinol Invest 35(2):174\u2013180","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"898_CR40","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11060-010-0326-2","volume":"102","author":"H Lv","year":"2011","unstructured":"Lv H et al (2011) Effects of estrogen receptor antagonist on biological behavior and expression of growth factors in the prolactinoma MMQ cell line. J Neurooncol 102(2):237\u2013245","journal-title":"J Neurooncol"},{"issue":"3","key":"898_CR41","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s11102-010-0283-y","volume":"14","author":"M Babey","year":"2011","unstructured":"Babey M et al (2011) Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary 14(3):222\u2013230","journal-title":"Pituitary"},{"issue":"11","key":"898_CR42","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jocn.2015.06.001","volume":"22","author":"TR Smith","year":"2015","unstructured":"Smith TR et al (2015) Current indications for the surgical treatment of prolactinomas. J Clin Neurosci 22(11):1785\u20131791","journal-title":"J Clin Neurosci"},{"issue":"1","key":"898_CR43","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11102-014-0563-z","volume":"18","author":"A Tirosh","year":"2015","unstructured":"Tirosh A et al (2015) Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary 18(1):108\u2013115","journal-title":"Pituitary"},{"issue":"11","key":"898_CR44","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.4158\/EP15804.OR","volume":"21","author":"A Tirosh","year":"2015","unstructured":"Tirosh A, Benbassat C, Shimon I (2015) Short-term decline in prolactin concentrations can predict future prolactin normalization, tumor shrinkage, and time to remission in men with macroprolactinomas. Endocr Pract 21(11):1240\u20131247","journal-title":"Endocr Pract"},{"key":"898_CR45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40842-015-0006-4","volume":"1","author":"A Tirosh","year":"2015","unstructured":"Tirosh A, Shimon I (2015) Management of macroprolactinomas. Clin Diabetes Endocrinol 1:5","journal-title":"Clin Diabetes Endocrinol"},{"key":"898_CR46","doi-asserted-by":"publisher","first-page":"e447e456","DOI":"10.1016\/j.wneu.2018.03.006","volume":"114","author":"K Elshazly","year":"2018","unstructured":"Elshazly K et al (2018) Clinical outcomes after endoscopic endonasal resection of giant pituitary adenomas. World Neurosurg 114:e447\u2013e456","journal-title":"World Neurosurg"},{"issue":"1","key":"898_CR47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1530\/EJE-07-0248","volume":"158","author":"J Kreutzer","year":"2008","unstructured":"Kreutzer J et al (2008) Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 158(1):11\u201318","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"898_CR48","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1530\/EJE-10-0961","volume":"164","author":"X Qu","year":"2011","unstructured":"Qu X et al (2011) Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases. Eur J Endocrinol 164(4):499\u2013504","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"898_CR49","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1210\/jc.2016-2008","volume":"101","author":"A Faje","year":"2016","unstructured":"Faje A et al (2016) Dopamine agonists can reduce cystic prolactinomas. J Clin Endocrinol Metab 101(10):3709\u20133715","journal-title":"J Clin Endocrinol Metab"},{"key":"898_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-018-0877-3","author":"SC Dogansen","year":"2018","unstructured":"Dogansen SC et al (2018) Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas. Pituitary. \n                    https:\/\/doi.org\/10.1007\/s11102-018-0877-3","journal-title":"Pituitary"},{"issue":"7","key":"898_CR51","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00234-015-1519-3","volume":"57","author":"J Kreutz","year":"2015","unstructured":"Kreutz J et al (2015) Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference. Neuroradiology 57(7):679\u2013684","journal-title":"Neuroradiology"},{"issue":"3","key":"898_CR52","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3346\/jkms.2005.20.3.489","volume":"20","author":"KI Paek","year":"2005","unstructured":"Paek KI et al (2005) Clinical significance of Ki-67 labeling index in pituitary macroadenoma. J Korean Med Sci 20(3):489\u2013494","journal-title":"J Korean Med Sci"},{"key":"898_CR53","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.clineuro.2018.02.001","volume":"167","author":"L Lv","year":"2018","unstructured":"Lv L et al (2018) Clinically aggressive phenotype: a clinicopathological case series of atypical pituitary adenomas. Clin Neurol Neurosurg 167:93\u201398","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"898_CR54","doi-asserted-by":"publisher","first-page":"G1G24","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot G et al (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178(1):G1\u2013G24","journal-title":"Eur J Endocrinol"},{"key":"898_CR55","doi-asserted-by":"publisher","first-page":"e213e221","DOI":"10.1016\/j.wneu.2018.01.142","volume":"113","author":"X Liu","year":"2018","unstructured":"Liu X et al (2018) Expression of matrix metalloproteinase-9, pituitary tumor transforming gene, high mobility group A 2, and Ki-67 in adrenocorticotropic hormone-secreting pituitary tumors and their association with tumor recurrence. World Neurosurg 113:e213\u2013e221","journal-title":"World Neurosurg"},{"issue":"12","key":"898_CR56","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s007010050432","volume":"141","author":"T Ozgen","year":"1999","unstructured":"Ozgen T et al (1999) Prolactin secreting pituitary adenomas: analysis of 429 surgically treated patients, effect of adjuvant treatment modalities and review of the literature. Acta Neurochir (Wien) 141(12):1287\u20131294","journal-title":"Acta Neurochir (Wien)"},{"issue":"7","key":"898_CR57","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1210\/jcem.87.7.8645","volume":"87","author":"M Losa","year":"2002","unstructured":"Losa M et al (2002) Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 87(7):3180\u20133186","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"898_CR58","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.3171\/foc.2004.16.4.3","volume":"16","author":"JK Liu","year":"2004","unstructured":"Liu JK, Couldwell WT (2004) Contemporary management of prolactinomas. Neurosurg Focus 16(4):E2","journal-title":"Neurosurg Focus"},{"issue":"8401","key":"898_CR59","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/S0140-6736(84)92596-0","volume":"2","author":"R Fahlbusch","year":"1984","unstructured":"Fahlbusch R et al (1984) Influence of preoperative bromocriptine therapy on success of surgery for microprolactinoma. Lancet 2(8401):520","journal-title":"Lancet"},{"issue":"3","key":"898_CR60","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s11102-008-0135-1","volume":"12","author":"ME Sughrue","year":"2009","unstructured":"Sughrue ME et al (2009) Pre-operative dopamine agonist therapy improves post-operative tumor control following prolactinoma resection. Pituitary 12(3):158\u2013164","journal-title":"Pituitary"},{"issue":"6966","key":"898_CR61","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1136\/bmj.309.6966.1409","volume":"309","author":"JA Thomson","year":"1994","unstructured":"Thomson JA et al (1994) Ten year follow up of microprolactinoma treated by transsphenoidal surgery. BMJ 309(6966):1409\u20131410","journal-title":"BMJ"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-018-0898-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-018-0898-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-018-0898-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T19:14:56Z","timestamp":1561230896000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-018-0898-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,23]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["898"],"URL":"https:\/\/doi.org\/10.1007\/s11102-018-0898-y","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,23]]},"assertion":[{"value":"23 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare no conflict of interest that could prejudice the study reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}